jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Renal SOL Biopsy

Biopsy
image

Report in 240Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Biopsy of renal space-occupying lesion.

₹555₹793

30% OFF

Renal SOL Biopsy - Comprehensive Medical Test Information Guide

  • Why is it done?
    • Test Description: A renal SOL (Solid or Space-Occupying Lesion) biopsy is a minimally invasive diagnostic procedure that involves obtaining a tissue sample from a suspicious solid mass or lesion detected in the kidney using ultrasound, CT, or MRI guidance.
    • Indications for Testing: • Diagnosis of renal masses of uncertain origin • Differentiation between benign and malignant kidney lesions • Confirmation of suspected renal cell carcinoma (RCC) • Evaluation of solid renal lesions greater than 1 cm in diameter • Assessment of metastatic disease to the kidney • Guidance for treatment planning and staging • Evaluation of lesions showing imaging characteristics concerning for malignancy • Cases where imaging findings are inconclusive or equivocal
    • Typical Timing: • Usually performed when a solid renal mass is identified on imaging studies • Often conducted before surgical intervention to confirm diagnosis • May be performed prior to ablative therapy to establish definitive histology • Typically scheduled as an outpatient procedure • Can be performed urgently if malignancy is suspected
  • Normal Range
    • Reference Values: • Normal Result (Negative): Benign renal tissue without malignant cells; normal kidney parenchyma with no evidence of neoplasm • Absence of: Atypical cells, dysplasia, or malignant transformation • No evidence of: Renal cell carcinoma, lymphoma, metastatic disease, or other malignancies
    • Result Interpretation Scale: • Benign (Normal): Pathologic findings consistent with benign renal disease (angiomyolipoma, oncocytoma, cysts) • Malignant (Abnormal): Histopathologic evidence of carcinoma or other malignancy • Indeterminate: Ambiguous findings requiring additional studies or clinical correlation • Inconclusive: Insufficient tissue for definitive diagnosis requiring repeat biopsy
    • Units of Measurement: • Histopathologic diagnosis (categorical classification) • Fuhrman grade (for renal cell carcinoma): Grades 1-4 based on nuclear morphology • WHO/ISUP grade for RCC: Grades 1-4 (lower grade = better prognosis) • Specimen adequacy: Adequate vs. inadequate tissue sampling
    • Normal vs. Abnormal Interpretation: • Normal: Benign histology supports conservative management or ablative therapy • Abnormal: Malignant diagnosis typically necessitates surgical intervention or oncologic management • Clinical significance: Results directly influence treatment strategy and patient prognosis
  • Interpretation
    • Detailed Result Interpretation: • Clear Cell Renal Cell Carcinoma (CCRCC): Most common malignant finding; shows clear cytoplasm with poor prognosis correlation • Papillary RCC: Shows papillary architecture; generally lower grade with better prognosis • Chromophobe RCC: Distinctive pale cells with characteristic features; intermediate prognosis • Oncocytoma (Benign): Composed of oncocytes; benign but cannot always be distinguished from chromophobe RCC • Angiomyolipoma: Benign fatty lesion; no follow-up needed if confirmed • Multilocular Cystic Lesion: Generally benign; minimal malignant potential
    • Clinical Significance of Different Patterns: • High-Grade Malignancy (Grade 3-4): Aggressive behavior; requires prompt treatment; higher metastatic potential • Low-Grade Malignancy (Grade 1-2): Slower progression; may allow for surveillance in selected cases • Benign Findings: Support for non-surgical management; ablation or surveillance may be appropriate • Indeterminate Results: Require correlation with imaging; may necessitate repeat biopsy or clinical follow-up
    • Factors Affecting Result Interpretation: • Specimen adequacy: Insufficient tissue may yield inconclusive results • Sampling location: Central vs. peripheral portions may show different histology • Crush artifact: May obscure cellular details and complicate diagnosis • Immunohistochemical staining: May be necessary for definitive classification • Molecular testing: Can provide additional diagnostic information and prognostic markers • Patient factors: Renal function, comorbidities, and life expectancy influence clinical significance
    • Prognostic Information: • Grade influences staging and survival outcomes • Histologic type affects treatment decisions and follow-up protocols • Presence of necrosis correlates with more aggressive disease • Vascular invasion, if identified, indicates higher risk of metastasis • Margin characteristics (if applicable) guide surgical extent
  • Associated Organs
    • Primary Organ System Involved: • Kidneys (renal system): Primary target organ • Secondary involvement: Potential metastatic spread to lungs, bones, liver, brain, adrenal glands • Urinary system: Complete urinary tract may be affected by metastatic disease
    • Medical Conditions Associated with Abnormal Results: • Renal Cell Carcinoma (RCC): Most common malignant kidney tumor • Von Hippel-Lindau (VHL) disease: Genetic predisposition to RCC • Hereditary Papillary RCC: Familial cancer syndrome • Birt-Hogg-Dubé Syndrome: Increased RCC risk • Tuberous Sclerosis Complex: Associated with renal angiomyolipomas and RCC • End-stage renal disease: Increased RCC risk • Chronic dialysis-associated cystic disease
    • Diseases Diagnosed or Monitored: • Primary renal malignancies • Metastatic disease to kidney • Renal lymphomas • Infection/abscess (differentiation from malignancy) • Benign renal tumors requiring differentiation from malignancy • Recurrent or residual disease post-treatment
    • Potential Complications from Abnormal Results: • Metastatic disease: Spread to lungs (60%), bones (30%), liver (20%), brain (10%) • Renal insufficiency: Progressive loss of renal function • Hypertension: Secondary to RCC-related renin production • Systemic effects: Paraneoplastic syndromes (fever, weight loss, anemia) • Mortality: 5-year survival varies by stage and grade (40-90%) • Treatment complications: Morbidity from required surgical or systemic therapy
  • Follow-up Tests
    • Recommended Follow-up Based on Results: • If Malignant Diagnosis: - Staging CT or MRI of abdomen/pelvis - Chest CT to evaluate for pulmonary metastases - Bone scan or skeletal survey if high-grade - Brain MRI if symptoms or high-risk features present - Laboratory studies: CBC, comprehensive metabolic panel, LDH - Chest X-ray (baseline and surveillance)
    • If Benign Diagnosis: - Imaging surveillance: Ultrasound or CT at 6 months, then annually for 2 years - Consider ablative therapy (cryotherapy or radiofrequency ablation) vs. surveillance - No additional laboratory testing typically required - Clinical follow-up for symptom assessment
    • If Indeterminate/Inconclusive Results: - Repeat biopsy with improved sampling technique - Enhanced imaging with multimodal approach - Close clinical and radiologic surveillance - Multidisciplinary team discussion for best management
    • Monitoring Frequency for Ongoing Conditions: • High-grade RCC: Every 3-4 months for first 2 years, then every 6 months • Low-grade RCC: Every 6-12 months after treatment • Post-treatment surveillance: Baseline at 1 month, then regular intervals based on grade and stage • Benign lesions managed conservatively: Imaging at 6 months, 12 months, then annually for 5 years
    • Complementary Tests Providing Additional Information: • Immunohistochemistry: Cytokeratin, vimentin, CD10 for RCC subtyping • Molecular testing: PBRM1, BAP1, SETD2 mutations for prognostic information • Flow cytometry: If lymphoma or leukemia suspected • Electron microscopy: Rarely needed for diagnosis • Renal artery ultrasound: To evaluate vascular involvement • Renal function tests: Baseline and post-biopsy assessment
  • Fasting Required?
    • Fasting Requirement: YES
    • Fasting Duration and Instructions: • NPO (nothing by mouth) for 4-6 hours before procedure • For morning procedures: Typically nothing after midnight • For afternoon procedures: Light breakfast permitted early morning, then NPO 4 hours prior • Clear fluids may be allowed up to 2 hours before procedure (confirm with facility) • Stay hydrated within fasting guidelines if directed
    • Medications to Avoid: • Anticoagulants (warfarin, dabigatran): Discontinue 3-5 days before biopsy • Antiplatelet agents (aspirin, clopidogrel, ticlopidine): Hold 5-7 days prior if possible • NSAIDs: Avoid for 5-7 days before procedure • Certain blood pressure medications: May need adjustment per physician • Review with interventional radiologist regarding specific medications • Do NOT discontinue cardiac medications without physician approval
    • Other Patient Preparation Requirements: • Pre-procedure laboratory work: - Coagulation studies (PT/INR, PTT) - Complete blood count - Renal function tests (creatinine, BUN) - Type and cross-match if complications anticipated
    • Additional Preparation: • Informed consent: Review risks, benefits, and alternatives • Allergies: Report all allergies, especially contrast or iodine allergies • Pregnancy status: Confirm non-pregnant status if female of childbearing age • Sedation planning: Arrange transportation if conscious sedation will be used • Vital sign assessment: Pre-procedure vital signs recorded • Patient education: Review procedure details and post-procedure expectations • Bathroom access: Void before procedure • Remove metallic objects: Jewelry, watches, eyeglasses
    • Post-Procedure Guidelines: • Resume normal diet after procedure completion • Gradual return to normal medications as directed • Anticoagulation restart: Typically 24 hours post-procedure if no bleeding • Activity restrictions: Avoid strenuous activity for 1-2 weeks • Hydration: Increase fluid intake to promote urine output • Monitor for complications: Hematuria, flank pain, fever

How our test process works!

customers
customers